1. Home
  2. XBIO

as of 12-12-2025 4:00pm EST

$2.44
+$0.02
+0.83%
Stocks Health Care Biotechnology: Pharmaceutical Preparations Nasdaq

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors.

Chart Type:
Time Range:
Founded: N/A Country:
United States
United States
Employees: N/A City: FRAMINGHAM
Market Cap: 5.9M IPO Year: N/A
Target Price: N/A AVG Volume (30 days): 47.3K
Analyst Decision: Hold Number of Analysts: 1
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.05 EPS Growth: N/A
52 Week Low/High: $2.20 - $13.93 Next Earning Date: 11-13-2025
Revenue: $2,858,935 Revenue Growth: 13.30%
Revenue Growth (this year): 1.99% Revenue Growth (next year): 20.00%

Latest Xenetic Biosciences Inc. News

XBIO Breaking Stock News: Dive into XBIO Ticker-Specific Updates for Smart Investing

All XBIO News

Share on Social Networks: